Drug intelligence / Profile preview

[18F]AlF-NOTA-QHY-04

Lead developer
Shandong Academy of Medical Sciences
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

`[18F]AlF-NOTA-QHY-04` is an investigational, fluorine-18 labeled, NOTA-conjugated cyclic polypeptide radiotracer designed for positron emission tomography (PET) imaging. It specifically targets C-X-C chemokine receptor type 4 (CXCR4), a G-protein coupled receptor that is highly overexpressed in various hematologic malignancies and solid tumors, as well as in inflammatory conditions. Developed by academic research groups in China, including the Shandong Cancer Hospital and Institute, the tracer utilizes an aluminum-fluoride ([18F]AlF) labeling strategy with the NOTA chelator, resulting in a highly hydrophilic complex with favorable pharmacokinetics, rapid renal clearance, and low background brain uptake. In clinical studies, [18F]AlF-NOTA-QHY-04 PET/CT has demonstrated high diagnostic accuracy and tumor-to-background contrast in detecting primary central nervous system lymphoma (PCNSL), small cell lung cancer (SCLC), and gliomas. It has also shown utility in predicting treatment response and progression-free survival in limited-stage SCLC patients undergoing chemoradiotherapy, as well as in the early detection of radiation-induced lung, brain, and esophageal injuries.

Other names
18F-AlF-labeled NOTA-conjugated polypeptide18F-AlF-NOTA-QHY-04 complexfluorine-18 labeled NOTA-conjugated polypeptidefluorine18 labeled NOTA-conjugated polypeptidefluorine 18 labeled NOTA-conjugated polypeptide
02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
Synonyms and codes
NOTA-QHY-04QHY-04
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
acquired brain injury (ABI)In developmentActive
acute lung injury syndromesIn developmentActive
colorectal cancer (CRC) and precursor lesionsIn developmentActive
diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)In developmentActive
hepatocellular carcinoma (HCC)In developmentActive
limited-stage small-cell lung cancer (LS-SCLC)In developmentActive
non-small-cell lung cancer (NSCLC)In developmentActive
pancreatic cancer and precursor lesionsIn developmentActive
primary central nervous system lymphoma (PCNSL)In developmentActive
radiation-induced cognitive impairment / radiation-induced cognitive dysfunction (RICI / RICD)In developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Shandong Academy of Medical SciencesLead developer
07

Competitive landscape

Drugs on the same target
49
Drugs in the lead indication
40

Lead indication: acquired brain injury (ABI)

Most advanced in the lead indication

  1. mavorixaforApproved
  2. motixafortideApproved
  3. plerixaforApproved
  4. acetaminophenPhase 4
  5. exenatidePhase 4

Beyond the preview

Go deeper on [18F]AlF-NOTA-QHY-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]AlF-NOTA-QHY-04.

Work on [18F]AlF-NOTA-QHY-04? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call